Recommendations Regarding Missed Dose (2.3) If a dose is missed, administer the missed dose as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose
The clinical trials showing an average 14.9% weight loss over 68 weeks used Wegovys 2.4 mg dose, so theoretically Wegovy might produce slightly better results
The fact that GLP1 medications work by enhancing natural hormonal processes rather than artificially stimulating the nervous system contributes to their favorable safety profile
Dedicated peptide suppliers often understand product handling requirements better than general supplement retailers
Additional serious risks include: Acute pancreatitis severe, persistent abdominal pain radiating to the back requires immediate medical attention Gallbladder disease rapid weight loss from any cause increases gallstone risk Acute kidney injury secondary to dehydration from vomiting/diarrhoea Hypoglycaemia increased risk when combined with insulin or sulfonylureas Aspiration risk during surgery delayed gastric emptying may require pre-operative fasting adjustments Contraindications Who Should Not Take Foundayo Orforglipron is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Pregnancy or planned pregnancy (discontinue at least 2 months before planned conception) Severe gastrointestinal disease including gastroparesis History of pancreatitis Type 1 diabetes Prior serious hypersensitivity reactions to any GLP-1 receptor agonist Critically, orforglipron should not be combined with other GLP-1 receptor agonists including Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, or Rybelsus
